## **Progress Report: Sri Lanka Clinical Trials Registry**

SLCTR registration number: SLCTR/2024/033				
Scientific title of trial: A Parallel-Group Treatment, Double-Blind, 2-Arm Study to Investigate the Comparative Efficacy, Safety, and Immunogenicity Between Intravenous AVT16 and Entyvio® in Male and Female Subjects Aged 18 to 80 Years Inclusive with Moderate to Severe Active Ulcerative Colitis				
Date of commencement (enrolment of first participant): 10 – Jan -2025				
Progression:	6 months ✓ 1 year □ 2 years □ 3  At completion □	years □		
1. Baseline data				
Any changes to the trial design/ methodology/ protocol after commencement: No				
Any changes to trial outcomes after commencement: No				
2. Current status				
Recruitment status: pending/ recruiting/ recruitment complete: follow up continuing/ recruitment complete: follow up complete/ recruitment suspended / recruitment terminated				
Number assessed for eligibility: 18				
Number recruited and allocated/randomized: 03				
Number allocated/randomized to each intervention/arm (please edit as relevant): <b>Pending</b>				
Arm 1:	:			
Arm 2:	:			
Losses/exclusions after allocation/randomization (please edit as relevant): <b>Pending</b>				
Arm 1:	:			
Arm 2:	:			

## 3. Trial output

Date of trial completion ("last patient, last visit"): Pending

Final sample size: **Pending** 

Summary of Interim/Final data (if available):

a	

Abstract presentations of results at scientific meetings Note: please include a URL link or scanned copy of the abstract

Title of Abstract	Full citation (please include authors, date, title of conference and place of presentation, page number of abstract).
Not applicable	

**Publications** 

Note: please include a URL link or scanned copy of the publication

Title of paper	Full citation (please include authors, title of journal, volume, issue and page numbers, and/or DOI)
Not applicable	

for;

Prof. ARJUNA DE SILVA
MBBS,MD,MRCP(UK),MSc(Oxon)
FRCP(Lond),FCCP,AGAF,FNASSL
Consultant Physician

Prof. Arjuna De Stiva

Coordinating Principal Investigator

Date: 28 Apr 2025